Here are seven key trends:
1. The market is expected to reach $2 billion by 2020.
2. It is currently valued at $1.6 billion.
3. The market is estimated to grow at a compound annual growth rate of 3.8 percent from 2015 to 2020.
4. Factors such as rapid rise in aging population and rising prevalence of cardiovascular and respiratory system-related diseases are driving the growth of the market.
5. But other factors such as side effects associated with ketamine usage and regulatory issues are likely to restrain the growth of this market.
6. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015.
7. Major players operating in the market are AstraZeneca, Baxter International and Hikma Pharmaceuticals.
More articles on anesthesia:
Screening pediatric patients before administering anesthesia reduces risk of respiratory adverse events: 5 insights
Dr. Nikolaos Skubas earns American Society of Echocardiography honor: 5 things to know
Rivanna Medical starts manufacturing its Accuro device: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
